Previous 10 | Next 10 |
- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conference call at 4:30 p.m. ET toda...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Voyager Therapeutics Inc. (VYGR) is expected to report $-0.58 for Q3 2023
2023-11-05 17:35:55 ET Major earnings expected after the bell on Monday include: Realty Income Corporation ( O ) Vertex Pharmaceuticals Incorporated ( VRTX ) NXP Semiconductors N.V. ( NXPI ) Alteryx ( AYX ) Tanger Factory Outlet Centers ( SKT ) ...
2023-11-03 12:46:55 ET More on Voyager Therapeutics Assessing Voyager's Alzheimer's Treatment Potential Seeking Alpha’s Quant Rating on Voyager Therapeutics Historical earnings data for Voyager Therapeutics Financial information for Voyager Therapeutic...
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monda...
2023-10-05 17:23:44 ET Gainers: nCino ( NASDAQ: NCNO ) +8% . TPI Composites ( TPIC ) +6% . SCYNEXIS ( SCYX ) +5% . Sutro Biopharma ( STRO ) +5% . Black Diamond Therapeutics ( BDTX ) +4% . Losers: SomaLogic ( SLGC ...
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Char...
2023-09-22 20:11:04 ET Summary Voyager Therapeutics shows strong financials with $272.8M liquidity and $4.9M Q2 collaboration revenue, yet R&D spending signals higher risk. The company's Alzheimer's gene therapies via TRACER technology are promising but in early stages, warran...
2023-08-07 13:47:21 ET Summary Two new Breakout Stocks for Week 32 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks cleared the 10% mark in less than a week with peak gains in PLTR +18.0% and ARDX +13.1%. The Momen...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...